“The ICCS was a great start to Bio2013, it was interesting to see the other cancer companies present and we made a few excellent contacts that otherwise we may not have connected with. I will certainly be present at ICCS 2014.” Richard Godfrey, CEO, BerGenBio

“We are at a development stage where we need to communicate what we are doing. It is impossible to have an overview over all possibilities for scientific sensible co-development. Participating at ICCS 2013 and presenting our project gave us the possibility to inform possible development partners in a way that makes it possible for them to see possible synergies with us.”Øyvind Arnesen, CEO, Ultimovacs

“Cancer Research Technology presented an immunotherapy spinout from the University of Birmingham at the 2013 ICCS event, and as
a result are now following up with two independent investors who expressed serious interest in the company.” Andrea Schivella, Cancer Research Technology

“I think the ICCS event was good. It gave us a number of contacts that seems valuable for further follow-up. I think the format also works well.” Odd Arild Lehne, CEO, PubGene